PEGASYS®2
No dose adjustment required for creatinine clearance
>20 mL/min
1. PEG-Intron™. PDR  ®. 56th ed. 2002. 
2. Martin P et al. Hepatology. 2000;32(suppl):370A.
Renal Impairment
Slide 16 Renal Impairment
Renal impairment does necessitate adjusting the dose of PEG-Intron™ (peginterferon alfa-2b [12KD]) in individuals with creatinine clearance less than 50 mL/min.
In contrast, reported pharmacokinetic results for PEGASYS® (peginterferon alfa-2a [40KD]) indicate that no change in dosing is required for patients with creatinine clearance >20 mL/min.2
Martin and associates administered single 90-g doses of PEGASYS® to one group of normal subjects and five groups of patients with varying degrees of renal impairment. Their analysis indicated that creatinine clearance of
40 mL/min or less and greater than 20 mL/min had only slight effects on the pharmacokinetic profile for PEGASYS®, and that patients with creatinine clearance greater than 20 mL/min required no dose adjustments.2


   1. PEG-Intron™. PDR  ®. 56th ed. 2002.  2. Martin P et al. Hepatology. 2000;32 (suppl):370A.